These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 16121129)
1. Can we develop neurally acting drugs for the treatment of migraine? Goadsby PJ Nat Rev Drug Discov; 2005 Sep; 4(9):741-50. PubMed ID: 16121129 [TBL] [Abstract][Full Text] [Related]
2. Future pharmacologic targets for acute and preventive treatments of migraine. Buchanan TM; Ramadan NM; Aurora S Expert Rev Neurother; 2004 May; 4(3):391-430. PubMed ID: 15853537 [TBL] [Abstract][Full Text] [Related]
3. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581 [TBL] [Abstract][Full Text] [Related]
4. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors. Gupta S; Villalón CM Pharmacol Ther; 2010 Oct; 128(1):170-90. PubMed ID: 20655327 [TBL] [Abstract][Full Text] [Related]
6. The discovery of a new drug class for the acute treatment of migraine. Humphrey PP Headache; 2007 Apr; 47 Suppl 1():S10-9. PubMed ID: 17425704 [TBL] [Abstract][Full Text] [Related]
7. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs. Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106 [TBL] [Abstract][Full Text] [Related]
8. The Role of 5-Hydroxytryptamine in the Pathophysiology of Migraine and its Relevance to the Design of Novel Treatments. Villalón CM; VanDenBrink AM Mini Rev Med Chem; 2017; 17(11):928-938. PubMed ID: 27465216 [TBL] [Abstract][Full Text] [Related]
10. Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine. Elkind AH; MacGregor EA Expert Rev Neurother; 2008 May; 8(5):723-36. PubMed ID: 18457529 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of migraine]. Hoffmann J; Reuter U Dtsch Med Wochenschr; 2007 Oct; 132(41):2153-8. PubMed ID: 17924297 [TBL] [Abstract][Full Text] [Related]
12. [Treatments of migraine]. Lucas C; Valade D Rev Prat; 2008 Mar; 58(6):625-37. PubMed ID: 18437951 [TBL] [Abstract][Full Text] [Related]
13. Side effects associated with current and prospective antimigraine pharmacotherapies. González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741 [TBL] [Abstract][Full Text] [Related]
14. Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects. Chan KY; Vermeersch S; de Hoon J; Villalón CM; Maassenvandenbrink A Pharmacol Ther; 2011 Mar; 129(3):332-51. PubMed ID: 21130807 [TBL] [Abstract][Full Text] [Related]
15. New migraine and pain research. Hargreaves R Headache; 2007 Apr; 47 Suppl 1():S26-43. PubMed ID: 17425708 [TBL] [Abstract][Full Text] [Related]
16. Early treatment in migraine: how strong is the current evidence? Gendolla A Cephalalgia; 2008 Sep; 28 Suppl 2():28-35. PubMed ID: 18715330 [TBL] [Abstract][Full Text] [Related]
18. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
19. [Triptans--pivotal event in migraine treatment]. Lusić I; Bilić I Acta Med Croatica; 2008 May; 62(2):173-8. PubMed ID: 18710081 [TBL] [Abstract][Full Text] [Related]
20. The multitarget drug approach in migraine treatment: the new challenge to conquer. González-Hernández A; Condés-Lara M Headache; 2014 Jan; 54(1):197-9. PubMed ID: 24400769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]